(Nevada, Las Vegas) United States, DelveInsight’s “Graves Ophthalmopathy – Pipeline Insight, 2023” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Graves Ophthalmopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Graves Ophthalmopathy Pipeline Report
Over 6+ companies and 6+ pipeline drugs in Alpha1-Antitrypsin Deficiency (AATD) pipeline landscape and their anticipated acceptance in the Graves Ophthalmopathy market would significantly increase market revenue.
Leading Graves Ophthalmopathy companies developing novel drug candidates to improve the Graves Ophthalmopathy treatment landscape include Novartis, Harbour, BioMed, Viridian Therapeutics, Inc., Suzhou Suncadia Biopharmaceuticals Co., Ltd., Sling Therapeutics, Inc., ValenzaBio Argenx, HanAll Biopharma
Promising Graves Ophthalmopathy pipeline therapies in various stages of development include Secukinumab, Batoclimab (HBM9161 and others
Graves Ophthalmopathy Overview
Graves eye disease, also called Graves’ Ophthalmopathy or Thyroid Eye disease, is a problem that usually develops in people with an overactive thyroid caused by Graves’ disease (See brochure on Graves’ disease). Graves’ disease is an autoimmune disease caused by antibodies directed against receptors present in the thyroid cells and also on the surface of the cells behind the eyes. Rarely can also affect the skin, usually the front part of the legs. This usually results in a generalized overactivity of the thyroid gland (hyperthyroidism). Up to one-half of people with Graves’ disease develop eye symptoms. These are usually mild and treatable. Eye symptoms most often begin within 6 months of diagnosis of Graves’ disease. Very rarely eye problems may develop long after the thyroid disease has been treated. In some patients with eye symptoms, hyperthyroidism never develops and, rarely, patients may be hypothyroid. The severity of the eye symptoms is not related to the severity of the hyperthyroidism.
Graves Ophthalmopathy Pipeline Analysis: Drug Profile
Secukinumab: Novartis
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat several chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Currently, it is in the Phase III stage of clinical trial evaluation to treat Graves’ ophthalmopathy.
Discover more about the emerging Graves Ophthalmopathy drugs @ Graves Ophthalmopathy Treatment Drugs
Graves Ophthalmopathy Pipeline Therapies and Key Companies
Batoclimab: Immunovant Sciences GmbH
Linsitinib: Sling Therapeutics
VRDN-001: Viridian Therapeutics
And many others
Graves Ophthalmopathy Pipeline Therapeutics Assessment
DelveInsight’s Report covers around 6+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Graves Ophthalmopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Drugs have been categorized under various product types like mono, Combination, and Mono/Combination.
Scope of the Graves Ophthalmopathy Pipeline Report
Coverage: Global
Key Alpha1 Antitrypsin Deficiency Companies: Novartis, Harbour BioMed, ViridianTherapeutics, Inc., Suzhou Suncadia Biopharmaceuticals Co., Ltd., Sling Therapeutics, Inc, ValenzaBio, Argenx, HanAll Biopharma, and others.
Key Graves Ophthalmopathy Pipeline Therapies: Secukinumab, Batoclimab (HBM9161), and many others.
Find out more about the Graves Ophthalmopathy treatment options in development @ Graves Ophthalmopathy Clinical Trials
Table of Contents
1. Graves Ophthalmopathy Introduction
2. Graves Ophthalmopathy Executive Summary
3. Graves Ophthalmopathy Overview
4. Graves Ophthalmopathy Pipeline Therapeutics
5. Graves Ophthalmopathy Late-Stage Products (Phase III)
6. Graves Ophthalmopathy Mid-Stage Products (Phase II)
7. Graves Ophthalmopathy Early Stage Products (Phase I/II)
8. Graves Ophthalmopathy Preclinical Stage Products
9. Graves Ophthalmopathy Discovery Stage Products
10. Graves Ophthalmopathy Therapeutic Assessment
11. Graves Ophthalmopathy Inactive Products
12. Graves Ophthalmopathy Collaborations Assessment- Licensing / Partnering / Funding
13. Graves Ophthalmopathy Unmet Needs
14. Graves Ophthalmopathy Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
